Skip to main content

Dr. Peter P. Lacamera, MD

Pulmonology (Pulmonary Disease Physician)

  • Medicare participating

At a glance

Years since graduation
29
In the NPI registry since
2006
Medicare patients seen, 2024
338

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1997Medical school: University of Massachusetts Medical School
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Pulmonary Disease Physician primary
    MA license 160330
  • Critical Care Medicine (Internal Medicine) Physician
    MA license 160330
  • Internal Medicine Physician
    MA license 160330

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Pulmonology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
338
Services billed
732
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes248178
Critical care, first 30-74 minutes17266
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes11565
Established patient office or other outpatient visit, 20-29 minutes6762
New patient office or other outpatient visit, 45-59 minutes4242
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes2323
Administration of influenza virus vaccine1717
Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage1616
Established patient office or other outpatient visit, 40-54 minutes1212
New patient office or other outpatient visit, 60-74 minutes1111

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Trelegy Ellipta (fluticasone/umeclidin/vilanter)
Other prescribers in Boston, MA
387
Albuterol Sulfate Hfa (albuterol sulfate)
Other prescribers in Boston, MA
271
Anoro Ellipta (umeclidinium brm/vilanterol tr)
Other prescribers in Boston, MA
101
Ventolin Hfa (albuterol sulfate)
Other prescribers in Boston, MA
87
Prednisone
Other prescribers in Boston, MA
77
Incruse Ellipta (umeclidinium bromide)
Other prescribers in Boston, MA
64
Breo Ellipta (fluticasone/vilanterol)
Other prescribers in Boston, MA
63
Ofev (nintedanib esylate)58
Arnuity Ellipta (fluticasone furoate)
Other prescribers in Boston, MA
48
Wixela Inhub (fluticasone propion/salmeterol)
Other prescribers in Boston, MA
48

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Industry-funded research

Named as a principal investigator on 7 industry-funded studies in 2025, from 3 companies. The companies reported $223,121 in research payments for these studies, mostly to the institutions running them.

  • An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis
    E.r. Squibb & Sons, L.l.c.
  • An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
    Boehringer Ingelheim International GmbH
  • PDE4 Phase III trial in PF-ILD
    Boehringer Ingelheim International GmbH
  • PDE4 Phase III trial in IPF patients
    Boehringer Ingelheim International GmbH

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Pulmonology clinicians in Boston

Sources

NPI registry (CMS NPPES, November 2026; record last updated March 17, 2025), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1124061759. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.